Quantification of biological range uncertainties in patients treated at the Krakow proton therapy centre.
Biological range extension
Monte Carlo
Proton therapy
Range uncertainties
Variable RBE
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
09 Mar 2022
09 Mar 2022
Historique:
received:
03
08
2021
accepted:
28
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
18
3
2022
Statut:
epublish
Résumé
Variable relative biological effectiveness (vRBE) in proton therapy might significantly modify the prediction of RBE-weighted dose delivered to a patient during proton therapy. In this study we will present a method to quantify the biological range extension of the proton beam, which results from the application of vRBE approach in RBE-weighted dose calculation. The treatment plans of 95 patients (brain and skull base patients) were used for RBE-weighted dose calculation with constant and the McNamara RBE model. For this purpose the Monte Carlo tool FRED was used. The RBE-weighted dose distributions were analysed using indices from dose-volume histograms. We used the volumes receiving at least 95% of the prescribed dose (V95) to estimate the biological range extension resulting from vRBE approach. The vRBE model shows higher median value of relative deposited dose and D95 in the planning target volume by around 1% for brain patients and 4% for skull base patients. The maximum doses in organs at risk calculated with vRBE was up to 14 Gy above dose limit. The mean biological range extension was greater than 0.4 cm. Our method of estimation of biological range extension is insensitive for dose inhomogeneities and can be easily used for different proton plans with intensity-modulated proton therapy (IMPT) optimization. Using volumes instead of dose profiles, which is the common method, is more universal. However it was tested only for IMPT plans on fields arranged around the tumor area. Adopting a vRBE model results in an increase in dose and an extension of the beam range, which is especially disadvantageous in cancers close to organs at risk. Our results support the need to re-optimization of proton treatment plans when considering vRBE.
Sections du résumé
BACKGROUND
BACKGROUND
Variable relative biological effectiveness (vRBE) in proton therapy might significantly modify the prediction of RBE-weighted dose delivered to a patient during proton therapy. In this study we will present a method to quantify the biological range extension of the proton beam, which results from the application of vRBE approach in RBE-weighted dose calculation.
METHODS AND MATERIALS
METHODS
The treatment plans of 95 patients (brain and skull base patients) were used for RBE-weighted dose calculation with constant and the McNamara RBE model. For this purpose the Monte Carlo tool FRED was used. The RBE-weighted dose distributions were analysed using indices from dose-volume histograms. We used the volumes receiving at least 95% of the prescribed dose (V95) to estimate the biological range extension resulting from vRBE approach.
RESULTS
RESULTS
The vRBE model shows higher median value of relative deposited dose and D95 in the planning target volume by around 1% for brain patients and 4% for skull base patients. The maximum doses in organs at risk calculated with vRBE was up to 14 Gy above dose limit. The mean biological range extension was greater than 0.4 cm.
DISCUSSION
CONCLUSIONS
Our method of estimation of biological range extension is insensitive for dose inhomogeneities and can be easily used for different proton plans with intensity-modulated proton therapy (IMPT) optimization. Using volumes instead of dose profiles, which is the common method, is more universal. However it was tested only for IMPT plans on fields arranged around the tumor area.
CONCLUSIONS
CONCLUSIONS
Adopting a vRBE model results in an increase in dose and an extension of the beam range, which is especially disadvantageous in cancers close to organs at risk. Our results support the need to re-optimization of proton treatment plans when considering vRBE.
Identifiants
pubmed: 35264184
doi: 10.1186/s13014-022-02022-5
pii: 10.1186/s13014-022-02022-5
pmc: PMC8905899
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50Subventions
Organisme : narodowe centrum badań i rozwoju
ID : POWR.03.02.00-00-I013/16
Organisme : fundacja na rzecz nauki polskiej
ID : POIR.04.04.00-00-2475/16-00
Informations de copyright
© 2022. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1097-1106
pubmed: 27869082
Radiat Oncol. 2018 Jan 16;13(1):6
pubmed: 29338744
Phys Med Biol. 2017 Sep 05;62(18):7482-7504
pubmed: 28873069
Radiat Oncol. 2019 Dec 30;14(1):243
pubmed: 31888769
Clin Transl Radiat Oncol. 2018 Feb 01;9:35-41
pubmed: 29594249
Phys Med Biol. 2020 Dec 17;65(24):245024
pubmed: 32554886
Phys Med Biol. 2015 Mar 21;60(6):2257-69
pubmed: 25715661
Radiat Oncol. 2016 May 17;11:68
pubmed: 27185038
Acta Oncol. 2011 Aug;50(6):763-71
pubmed: 21767172
Med Phys. 2014 Jun;41(6):064301
pubmed: 24877844
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):747-757
pubmed: 30395906
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):70-77
pubmed: 27084630
Med Phys. 2013 Dec;40(12):121719
pubmed: 24320505
Med Phys. 2015 Nov;42(11):6234-47
pubmed: 26520716
Med Phys. 2013 Nov;40(11):111716
pubmed: 24320424
Sci Rep. 2020 Apr 10;10(1):6212
pubmed: 32277106
Acta Oncol. 2017 Nov;56(11):1379-1386
pubmed: 28918679
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
Med Phys. 2012 Nov;39(11):6818-37
pubmed: 23127075
Biometrics. 1947 Sep;3(3):119-22
pubmed: 18903631
Phys Med. 2020 Feb;70:49-57
pubmed: 31968277
Adv Radiat Oncol. 2018 Dec 13;4(1):156-167
pubmed: 30706024
Phys Med Biol. 2012 Mar 7;57(5):1159-72
pubmed: 22330133
Phys Med Biol. 2015 Jul 07;60(13):5053-70
pubmed: 26061666
Phys Med Biol. 2020 Feb 10;65(4):045002
pubmed: 31851957
J Med Phys. 2016 Jul-Sep;41(3):192-7
pubmed: 27651566
Phys Med Biol. 2015 Nov 7;60(21):8399-416
pubmed: 26459756
Phys Med Biol. 2018 Nov 09;63(22):225009
pubmed: 30412471
Radiat Environ Biophys. 1997 Feb;36(1):59-66
pubmed: 9128899
Br J Radiol. 2020 Mar;93(1107):20190582
pubmed: 31778317
Radiother Oncol. 2021 Oct;163:177-184
pubmed: 34480959
Med Dosim. 2018 Summer;43(2):168-176
pubmed: 29650302
CNS Oncol. 2014 Mar;3(2):149-58
pubmed: 25055020
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Br J Radiol. 2020 Mar;93(1107):20190334
pubmed: 31738081